1. Humoral response to coronavirus disease-19 vaccines is dependent on dosage and timing of rituximab in patients with rheumatoid arthritis. Issue Volume 61:Issue S12(2020) (4th April 2022) Authors: van der Togt, Céleste J T; Ten Cate, David F; den Broeder, Nathan; Rahamat-Langendoen, Janette; van den Bemt, Bart J F; den Broeder, Alfons A Journal: Rheumatology Issue: Volume 61:Issue S12(2020) Page Start: SI175 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Rituximab dose-dependent infection risk in rheumatoid arthritis is not mediated through circulating immunoglobulins, neutrophils or B cells. (10th June 2022) Authors: Opdam, Merel A A; de Leijer, J H; den Broeder, Nathan; Thurlings, Rogier M; van der Weele, Wilfred; Nurmohamed, Michael T; Kok, Marc R; van Bon, Lenny; Ten Cate, David F; Verhoef, Lise M; den Broeder, Alfons A Journal: Rheumatology Issue: Volume 62:Number 1(2023) Page Start: 330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Seroconversion after a third COVID-19 vaccine is affected by rituximab dose but persistence is not in patients with rheumatoid arthritis. (24th August 2022) Authors: van der Togt, Céleste J T; Ten Cate, David F; van den Bemt, Bart J F; Rahamat-Langendoen, Janette; den Broeder, Nathan; den Broeder, Alfons A Journal: Rheumatology Issue: Volume 62:Number 4(2023) Page Start: 1627 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗